Literature DB >> 26838190

2-Deoxy-d-Glucose (2-DG)-Induced Cardiac Toxicity in Rat: NT-proBNP and BNP as Potential Early Cardiac Safety Biomarkers.

P S Terse1, P S Joshi2, N R Bordelon3, A M Brys4, K M Patton4, T P Arndt5, T P Sutula6.   

Abstract

2-Deoxy-d-glucose (2-DG) is being developed as a potential anticonvulsant and disease-modifying agent for patients with epilepsy; however, during preclinical development, cardiac toxicity has been encountered in rats. This study was performed to determine whether cardiac troponin (cTnI and cTnT), atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), N-terminal pro-brain natriuretic peptide (NT-proBNP), and/or creatine kinase (CK) could be useful as indicators of 2-DG cardiac toxicity. In addition, this study also investigated the association of cardiac histopathological changes with these biomarkers. F344 rats (4/sex/group/sacrifice point) were gavaged with either vehicle or 2-DG (50, 125, or 375 mg/kg twice daily; total daily dose of 100, 250, or 750 mg/kg/d) for 7, 14, 21, or 45 days followed by a 15-day recovery. Dose-dependent increases in NT-proBNP and BNP plasma concentrations were observed. Following recovery period, the NT-proBNP and BNP concentrations returned to baseline levels. There were no remarkable increases in CK, ANP, cTnI, or cTnT concentrations. There were no gross cardiac lesions observed at the necropsy. Microscopic findings of vacuolar degeneration and hypertrophy of the endothelial cells of the endocardium were present in the heart at doses of 250 and 750 mg/kg/d. Microscopic findings, in general, were associated with increases in NT-proBNP levels. Cardiac toxicity appeared to be reversible. In conclusion, NT-proBNP and BNP are potential early biomarkers for 2-DG-induced cardiac toxicity that can be useful to monitor 2-DG therapy in clinical trials.
© The Author(s) 2016.

Entities:  

Keywords:  2-deoxy-d-glucose; BNP; NT-proBNP; vacuolar degeneration

Mesh:

Substances:

Year:  2016        PMID: 26838190      PMCID: PMC4864115          DOI: 10.1177/1091581815624397

Source DB:  PubMed          Journal:  Int J Toxicol        ISSN: 1091-5818            Impact factor:   2.032


  25 in total

Review 1.  Troponin I: inhibitor or facilitator.

Authors:  S V Perry
Journal:  Mol Cell Biochem       Date:  1999-01       Impact factor: 3.396

2.  Structure of the core domain of human cardiac troponin in the Ca(2+)-saturated form.

Authors:  Soichi Takeda; Atsuko Yamashita; Kayo Maeda; Yuichiro Maéda
Journal:  Nature       Date:  2003-07-03       Impact factor: 49.962

Review 3.  Antiepileptic popular ketogenic diet: emerging twists in an ancient story.

Authors:  Joseph Vamecq; Louis Vallée; Florian Lesage; Pierre Gressens; James P Stables
Journal:  Prog Neurobiol       Date:  2005-01-27       Impact factor: 11.685

Review 4.  Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity.

Authors:  Michaela Adamcova; Martin Sterba; Tomas Simunek; Anna Potacova; Olga Popelova; Yvona Mazurova; Vladimir Gersl
Journal:  Expert Opin Drug Saf       Date:  2005-05       Impact factor: 4.250

5.  Ketonemia and seizures: metabolic and anticonvulsant effects of two ketogenic diets in childhood epilepsy.

Authors:  P R Huttenlocher
Journal:  Pediatr Res       Date:  1976-05       Impact factor: 3.756

Review 6.  Mechanisms of atrial natriuretic peptide secretion from the atrium.

Authors:  John R Dietz
Journal:  Cardiovasc Res       Date:  2005-10-01       Impact factor: 10.787

7.  Enzymic and cerebral metabolic effects of 2-deoxy-D-glucose.

Authors:  R W Horton; B S Meldrum; H S Bachelard
Journal:  J Neurochem       Date:  1973-09       Impact factor: 5.372

8.  Serum creatine kinase isoenzymes: a review.

Authors:  A A Nanji
Journal:  Muscle Nerve       Date:  1983-02       Impact factor: 3.217

9.  Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide.

Authors:  T Omland; A Aakvaag; V V Bonarjee; K Caidahl; R T Lie; D W Nilsen; J A Sundsfjord; K Dickstein
Journal:  Circulation       Date:  1996-06-01       Impact factor: 29.690

10.  B-type natriuretic peptide in cardiovascular disease.

Authors:  James A de Lemos; Darren K McGuire; Mark H Drazner
Journal:  Lancet       Date:  2003-07-26       Impact factor: 79.321

View more
  3 in total

1.  Glycolytic inhibition by 2-deoxy-d-glucose abolishes both neuronal and network bursts in an in vitro seizure model.

Authors:  Li-Rong Shao; Carl E Stafstrom
Journal:  J Neurophysiol       Date:  2017-04-12       Impact factor: 2.714

2.  Glycolytic inhibitor 2-deoxyglucose prevents cortical hyperexcitability after traumatic brain injury.

Authors:  Jenny B Koenig; David Cantu; Cho Low; Mary Sommer; Farzad Noubary; Danielle Croker; Michael Whalen; Dong Kong; Chris G Dulla
Journal:  JCI Insight       Date:  2019-04-30

Review 3.  Dysregulated Glucose Metabolism as a Therapeutic Target to Reduce Post-traumatic Epilepsy.

Authors:  Jenny B Koenig; Chris G Dulla
Journal:  Front Cell Neurosci       Date:  2018-10-16       Impact factor: 5.505

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.